Login / Signup

Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).

Anuja NeveBibha DasJakub WojtowiczZhiyue HuangSzofia BullainMichelle WatkinDominik LottTobias BittnerPaul DelmarGregory KleinCarsten HofmannGeoffrey A KerchnerJanice SmithMonika BaudlerPaulo FontouraRachelle S Doody
Published in: Journal of Alzheimer's disease : JAD (2024)
SC gantenerumab at doses of up to 1,200 mg Q4W were well tolerated in participants with mild AD dementia.
Keyphrases
  • phase iii
  • open label
  • double blind
  • clinical trial
  • phase ii
  • placebo controlled
  • phase ii study
  • study protocol
  • mild cognitive impairment
  • cognitive decline
  • cognitive impairment
  • squamous cell carcinoma